IP Library › Granted Patent US 12,329,808
Granted Patent B2
US 12,329,808 · App. 18/394,580 · Granted Jun 17, 2025

Compositions and methods for generating an immune response to treat or prevent malaria

Inventors: Farshad Guirakhoo (Atlanta, GA); Arban Domi (Atlanta, GA); Nathanael Paul McCurley (Decatur, GA)
Assignee: GeoVax, Inc.
A61K39/015A61K9/0019A61K47/6901A61P33/06A61K2039/5256A61K2039/54
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,329,808
App. No.
18/394,580
Granted
Jun 17, 2025
Kind
B2
Abstract

The compositions and methods are described for generating an immune response to a Plasmodium antigen. The compositions and methods described herein relate to a modified vaccinia Ankara (MVA) vector encoding one or more viral antigens for generating a protective immune response to malaria by expressing the Plasmodium antigen in the subject to which the MVA vector is administered. The compositions and methods of the present invention are useful both prophylactically and therapeutically and may be used to prevent and/or treat malaria.

Claims (27)

1. A pharmaceutical composition comprising at least one recombinant modified vaccinia Ankara (MVA) viral vector and a pharmaceutically acceptable adjuvant, wherein the recombinant MVA viral vector comprises:

i) a first nucleic acid sequence encoding a Plasmodium falciparum immunogenic polypeptide selected from the group consisting of circumsporozoite protein (CSP) and gametocyte surface protein P230 (Pfs230), the Plasmodium falciparum immunogenic polypeptide further comprising a transmembrane domain of a glycoprotein (GP) of Marburg virus; and

ii) a second nucleic acid sequence encoding a Marburg virus VP40 matrix protein;

wherein the CSP immunogenic polypeptide comprises the amino acid sequence of SEQ ID NO: 2, or an amino acid sequence at least 98% identical thereto;

wherein the Pfs230 immunogenic polypeptide comprises the amino acid sequence of SEQ ID NO: 6, or an amino acid sequence at least 98% identical thereto;

wherein the Marburg virus VP40 matrix protein comprises the amino acid sequence of SEQ ID NO: 8, or an amino acid sequence at least 98% identical thereto;

wherein both the first nucleic acid and the second nucleic acid sequence are under the control of promoters compatible with poxvirus expression systems; and,

wherein upon expression, the Plasmodium falciparum immunogenic polypeptide and Marburg virus VP40 matrix protein are capable of assembling together to form virus like particles (VLPs).

2. The pharmaceutical composition of claim 1 , wherein the at least one recombinant MVA viral vector is formulated for intraperitoneal, intramuscular, intradermal, epidermal, mucosal, or intravenous administration.

3. The pharmaceutical composition of claim 1 , wherein the adjuvant is an immune response enhancer.

4. The pharmaceutical composition of claim 1 , wherein the first nucleic acid sequence is inserted between MVA genes 18R and GIL; and the second nucleic acid sequence is inserted into restructured and modified deletion site III between MVA genes A50R and BIR.

5. The pharmaceutical composition of claim 1 , wherein the promoter is selected from the group consisting of Pm2H5, Psyn II, and mH5 promoters, and combinations thereof.

6. The pharmaceutical composition of claim 1 , wherein the first nucleic acid and second nucleic acid sequence are optimized by one or more methods selected from the group consisting of: changing selected codons to other synonymous codons that are optimal for protein expression by MVA, interrupting homopolymer stretches using silent mutations, and interrupting transcription terminator motifs using silent mutations.

7. The pharmaceutical composition of claim 1 , wherein the Plasmodium falciparum immunogenic polypeptide is CSP.

8. The pharmaceutical composition of claim 7 , wherein the first nucleic acid sequence comprises the nucleic acid sequence of SEQ ID NO: 1.

9. The pharmaceutical composition of claim 7 , wherein the second nucleic acid sequence comprises the nucleic acid sequence of SEQ ID NO: 7.

10. The pharmaceutical composition of claim 1 , wherein the Plasmodium falciparum immunogenic polypeptide is Pfs230.

11. The pharmaceutical composition of claim 10 , wherein the second nucleic acid sequence comprises the nucleic acid sequence of SEQ ID NO: 7.

12. A method of inducing an immune response in a subject in need thereof comprising administering an effective amount of the pharmaceutical composition of claim 1 to the subject.

13. The method of claim 12 , wherein the immune response is selected from a humoral immune response, a cellular immune response, or a combination thereof.

14. The method of claim 12 , wherein the immune response comprises (i) production of binding antibodies or neutralizing antibodies against the Plasmodium antigen, or (ii) production of non-neutralizing antibodies against the Plasmodium antigen.

15. The method of claim 12 , wherein the immune response comprises production of a cell-mediated immune response against the Plasmodium antigen.

16. The method of claim 12 , wherein the subject is a human.

17. The pharmaceutical composition of claim 1 ,

wherein the CSP immunogenic polypeptide comprises the amino acid sequence of SEQ ID NO: 2;

wherein the Pfs230 immunogenic polypeptide comprises the amino acid sequence of SEQ ID NO: 6; and,

wherein the Marburg virus VP40 matrix protein comprises the amino acid sequence of SEQ ID NO: 8.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 29, 2024
From: GUIRAKHOO, FARSHAD; DOMI, ARBAN; MCCURLEY, NATHANAEL PAUL
To: GEOVAX, INC.
Reel/Frame 066281/0934 →
Continuity (4)
Continuation 17726254 · Apr 21, 2022
Continuation 16648693
Provisional Application 62560405 · Sep 19, 2017
Related Publication 20240398922A1 · Dec 5, 2024
References Cited (137)
US 4603112A · Paoletti et al. · 1986 [cited by applicant]
US 4722848A · Paoletti et al. · 1988 [cited by applicant]
US 4769330A · Paoletti et al. · 1988 [cited by applicant]
US 5445953A · Dorner et al. · 1995 [cited by applicant]
US 6103244A · Dorner et al. · 2000 [cited by applicant]
US 6440422B1 · Sutter et al. · 2002 [cited by applicant]
US 6696281B1 · Chambers et al. · 2004 [cited by applicant]
US 6998252B1 · Moss et al. · 2006 [cited by applicant]
US 7015024B1 · Moss et al. · 2006 [cited by applicant]
US 7045136B1 · Moss et al. · 2006 [cited by applicant]
US 7045313B1 · Moss et al. · 2006 [cited by applicant]
US 7550147B2 · Howley et al. · 2009 [cited by applicant]
US 7795017B2 · Robinson et al. · 2010 [cited by applicant]
US 8288125B2 · Howley et al. · 2012 [cited by applicant]
US 8309326B2 · Howley et al. · 2012 [cited by applicant]
US 8414900B2 · Howley et al. · 2013 [cited by applicant]
US 8435543B2 · Howley et al. · 2013 [cited by applicant]
US 8623379B2 · Robinson et al. · 2014 [cited by applicant]
US 8900595B2 · Kawaoka et al. · 2014 [cited by applicant]
US 8916172B2 · Moss et al. · 2014 [cited by applicant]
US 9133478B2 · Moss et al. · 2015 [cited by applicant]
US 9133480B2 · Moss et al. · 2015 [cited by applicant]
US 9453239B2 · Moss et al. · 2016 [cited by applicant]
US 9683020B2 · Compans et al. · 2017 [cited by applicant]
US 9879231B2 · Moss et al. · 2018 [cited by applicant]
US 10072058B2 · Wang et al. · 2018 [cited by applicant]
US 11311612B2 · Guirakhoo · 2022 [cited by examiner]
US 11857611B2 · Guirakhoo · 2024 [cited by examiner]
US 20030215794A1 · Kawaoka et al. · 2003 [cited by applicant]
US 20040109876A1 · Yamamoto et al. · 2004 [cited by applicant]
US 20050036985A1 · Ensoli · 2005 [cited by applicant]
US 20050214256A1 · Megede et al. · 2005 [cited by applicant]
US 20060088909A1 · Compans et al. · 2006 [cited by applicant]
US 20060099225A1 · Bavari et al. · 2006 [cited by applicant]
US 20060127413A1 · Sutter et al. · 2006 [cited by applicant]
US 20060216702A1 · Compans et al. · 2006 [cited by applicant]
US 20070160627A1 · Staib et al. · 2007 [cited by applicant]
US 20080193483A1 · Moss et al. · 2008 [cited by applicant]
US 20080199493A1 · Picker et al. · 2008 [cited by applicant]
US 20090092628A1 · Mullins et al. · 2009 [cited by applicant]
US 20100047277A1 · Compans et al. · 2010 [cited by applicant]
US 20100143402A1 · Moss et al. · 2010 [cited by applicant]
US 20100196419A1 · Compans et al. · 2010 [cited by applicant]
US 20100330190A1 · Compans et al. · 2010 [cited by applicant]
US 20110104199A1 · Moss et al. · 2011 [cited by applicant]
US 20120052082A1 · Compans et al. · 2012 [cited by applicant]
US 20120219576A1 · Branco et al. · 2012 [cited by applicant]
US 20130101618A1 · Sullivan et al. · 2013 [cited by applicant]
US 20130280215A1 · Robinson · 2013 [cited by applicant]
US 20140322265A1 · Chaplin et al. · 2014 [cited by applicant]
US 20150299290A1 · Boons et al. · 2015 [cited by applicant]
US 20160040135A1 · Moss et al. · 2016 [cited by applicant]
US 20160144011A1 · Collins et al. · 2016 [cited by applicant]
US 20160251406A1 · Schlom et al. · 2016 [cited by applicant]
US 20170304427A1 · Volkmann et al. · 2017 [cited by applicant]
US 20190030157A1 · Guirakhoo et al. · 2019 [cited by applicant]
US 20190117758A1 · Robinson et al. · 2019 [cited by applicant]
US 20190184009A1 · Guirakhoo et al. · 2019 [cited by applicant]
US 20190290745A1 · Robinson et al. · 2019 [cited by applicant]
US 20190382453A1 · Robinson · 2019 [cited by applicant]
US 20230040403A1 · Robinson et al. · 2023 [cited by applicant]
US 20240156940A1 · Robinson et al. · 2024 [cited by applicant]
EP 0538496A1 · 1993 [cited by applicant]
EP 2402451A2 · 2012 [cited by applicant]
WO WO1994012617A1 · 1994 [cited by applicant]
WO WO1998008539A1 · 1998 [cited by applicant]
WO WO1999063062A1 · 1999 [cited by applicant]
WO WO2000003030A1 · 2000 [cited by applicant]
WO WO2002072754A2 · 2002 [cited by applicant]
WO WO2003078640A2 · 2003 [cited by applicant]
WO WO2003097845A1 · 2003 [cited by applicant]
WO WO2004048582A2 · 2004 [cited by applicant]
WO WO2005048957A2 · 2005 [cited by applicant]
WO WO2006026667A2 · 2006 [cited by applicant]
WO WO2007012691A1 · 2007 [cited by applicant]
WO WO2008142479A2 · 2008 [cited by applicant]
WO WO2010062757A1 · 2010 [cited by applicant]
WO WO2011047031A2 · 2011 [cited by applicant]
WO WO2011103417A2 · 2011 [cited by applicant]
WO WO2013059498A1 · 2013 [cited by applicant]
WO WO2014005958A1 · 2014 [cited by applicant]
WO WO2015009946A1 · 2015 [cited by applicant]
WO WO2015066715A1 · 2015 [cited by applicant]
WO WO2015175340A1 · 2015 [cited by applicant]
WO WO2016034678A2 · 2016 [cited by applicant]
WO WO2016068919A1 · 2016 [cited by applicant]
WO WO2016115116A1 · 2016 [cited by applicant]
WO WO2017120577A1 · 2017 [cited by applicant]
WO WO2017136419A1 · 2017 [cited by applicant]
WO WO2017143016A1 · 2017 [cited by applicant]
WO WO2017210181A1 · 2017 [cited by applicant]
WO WO2018195447A1 · 2018 [cited by applicant]
WO WO2019018501A1 · 2019 [cited by applicant]
WO WO2019040846A1 · 2019 [cited by applicant]
WO WO2019060356A1 · 2019 [cited by applicant]
WO WO2020247547A1 · 2020 [cited by applicant]
Coler et al. 2009 (Adjuvants for Malaria vaccines; Parasite Immunology 31:520-528). (Year: 2009). [cited by examiner]
U.S. Pat. No. 11,052,148, B2, U.S. Appl. No. 16/305,305, Guirakhoo et al., Jul. 6, 2021. [cited by applicant]
U.S. Pat. No. 11,278,607, B2, U.S. Appl. No. 16/068,527, Robinson et al., Mar. 22, 2022. [cited by applicant]
U.S. Pat. No. 11,311,612, B2, U.S. Appl. No. 16/648,693, Guirakhoo et al., filed Apr. 6, 2022. [cited by applicant]
U.S. Pat. No. 11,701,418, B2, U.S. Appl. No. 15/543,139, Robinson et al., filed Jul. 18, 2023. [cited by applicant]
U.S. Pat. No. 11,413,341, B2, U.S. Appl. No. 16/796,350, Robinson et al., filed Aug. 16, 2022. [cited by applicant]
U.S. Pat. No. 11,638,750, B2, U.S. Appl. No. 17/000,768, Guirakhoo et al., filed May 5, 2023. [cited by applicant]
U.S. Pat. No. 11,801,299, B2, U.S. Appl. No. 17/368,761, Guirakhoo et al., filed Oct. 31, 2023. [cited by applicant]
U.S. Pat. No. 11,857,611, B2, U.S. Appl. No. 17/726,254, Guirakhoo et al., filed Jan. 2, 2024. [cited by applicant]
U.S. Pat. No. 11,896,657, B2, U.S. Appl. No. 17/584,231, Robinson et al., filed Feb. 13, 2024. [cited by applicant]
U.S. Pat. No. 11,897,919, B2, U.S. Appl. No. 17/409,574, Robinson et al., filed Feb. 13, 2024. [cited by applicant]
Adu-Gyamfi et al., “The Ebola Virus Matrix Protein Penetrates into the Plasma Membrane,” J. Infect. Dis., vol. 210, No. 1, pp. 99-110, Jan. 7, 2014. [cited by applicant]
Alharbi et al., “Enhancing cellular immunogenicity of MVA-vectored vaccines by utilizing the F11 lendogenous promoter”, Vaccine, 34(1), 49-55, 2015. [cited by applicant]
Antoine et al., “The complete genomic sequence of the modified vaccinia ankara strain: Comparison with other orthpoxviruses”, Virology, 244, 365-396, 1998. [cited by applicant]
Brault, A.C., Domi, A., McDonald, E. et al., “A Zika Vaccine Targeting NS1 Protein Protects Immunocompetent Adult Mice in a Lethal Challenge Model,” Sci Rep 7, 14769, https://doi.org/10.1038/s41598-017-15039-8, 2017. [cited by applicant]
Cavenaugh, J.S. et al., Partially Randomized, Non-Blinded Trial of DNA and MVA Therapeutic 4, 17,22,23 Vaccines Based on Hepatitis B Vims Surface Protein for Chronic HBV Infection. Plos ONE., vol. 6, Issue 2, Feb. 15, 2… [cited by applicant]
Coler et al., “Adjuvants for Malaria vaccines,” Parasite Immunology, 31:520-528, 2009. [cited by applicant]
Domi, A., Feldmann, F., Basu, R. et al., “A Single Dose of Modified Vaccinia Ankara expressing Ebola Virus Like Particles Protects Nonhuman Primates from Lethal Ebola Virus Challenge,” Sci Rep 8, 864, https://doi.org/10… [cited by applicant]
Earl et al., “Recombinant modified vaccinia virus ankara provides durable protection against disease caused by immunodeficiency virus as well as long term immunity to an orthopoxvirus in a non-human primate,” Virology, … [cited by applicant]
GenBank Accession AFV31202, Glycoprotein [Marburg marburgvirus], 2013. [cited by applicant]
Goepfert PA et al., National Institutes of Allergy and Infectious Diseases HIV Vaccines Trials Network., “Specificity and 6-month durability of immune responses induced by DNA and recombinant modified vaccinia Ankara va… [cited by applicant]
Goepfert PA, et al., “National Institute of Allergy and Infectious Diseases HIV Vaccine Trials Network. Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1… [cited by applicant]
International Search Report and Written Opinion for PCT/US2018/051652, dated Feb. 11, 2019. [cited by applicant]
Iyer, S.S et al., “Codelivery of Envelope Protein in Alum with MVA Vaccine Induces CXCR3-Biased CXCR5 + and CXCR5 − CD4 T Cell Responses in Rhesus Macaques”, The Journal of Immunology, US, vol. 195, No. 3, doi: 10.4049/… [cited by applicant]
Mackett et al., “Vaccinia virus expression vectors”, J. Gen. Virology, 67, 2067-2082, 1986. [cited by applicant]
Malherbe, Delphine C. et al., “Modified vaccinia Ankara vaccine expressing Marburg virus-like particles protects guinea pigs from lethal Marburg virus infection”, Vaccines, 5(1), 78, 2020. [cited by applicant]
Manuel, E.R. et al., “Intergenic region 3 of modified vaccinia ankara is a functional site for insert gene expression and allows for potent antigenA-specific immune responses”, Virology, Elsevier, Amsterdam, NL, 2010, 4… [cited by applicant]
Mittler et al., “The Cytoplasmic Domain of Marburg Virus GP Modulates Early Steps of Viral Infection,” Journal of Virology, vol. 85, No. 6, pp. 8188-8196, Jun. 15, 2011. [cited by applicant]
Moss et al., “Reflections on the early development of poxvirus vectors”, Vaccine, 31(39), 4220-4222, 2013. [cited by applicant]
Orubu et al., “Expression and cellular immunogenicity of a transgenic antigen driven by endogenous poxviral early promoters at their authentic loci in MVA”, PLOS One, 7(6), e40167 doi: 10.1371/journal.pone.0040167, 2012. [cited by applicant]
Salvato et al., “A Single Dose of Modified Vaccinia Ankara Expressing Lassa Virus-like Particles Protects Mice from Lethal Intra-cerebral Virus Challenge”, Pathogens, 8:133, 2019. [cited by applicant]
Staib et al., “Transient host range selection for genetic engineering of modified vaccinia virus ankara”, Biotechniques, 28, 1137-1148, 2000. [cited by applicant]
Swenson et al., “Generation of Marburg virus-like particles by co-expression of glycoprotein and matrix protein”, FEMS Immunology and Medical Microbiology, 40(1), pp. 27-31, 2004. [cited by applicant]
Thompson, M. et al., “DNA/MVA Vaccination of HIV-1 Infected Participants with Viral Suppression on Antiretroviral Therapy, followed by Treatment Interruption: Elicitation of Immune Responses without Control of Re-Emerge… [cited by applicant]
Timm et al., “Genetic stability of recombinant MVA-BN”, Vaccine, 24, 4618-4621, 2006. [cited by applicant]
Urata, S. and Yasuda, J., “Cis- and cell-type-dependent trans-requirements for Lassa virus-like particle production”, J. Gen. Virol., 96 Pt 7, 1626-1635, 2015. [cited by applicant]
Vietheer et al., “Immunizations with chimeric hepatitis B virus-like particles to induce potential anti-hepatitis C virus neutralizing antibodies”, Antiviral Therapy, 12, 477-487, 2007. [cited by applicant]
Wang et al., “Modified H5 promoter improves stability of insert genes while maintaining immunogenicity during extended passage of genetically engineered MVA vaccines”, Vaccine, 28(6): 1547, Feb. 10, 2010. [cited by applicant]
Wyatt et al., “Development of a replication-deficient recombinant vaccinia virus vaccine effective against parainfluenza virus 3 infection in an animal model”, Vaccine, 14(15), 1451-1458, 1996. [cited by applicant]
Xiaoying, Shen et al., “HIV gp120 and Modified Vaccinia Virus Ankara (MVA) gp140 Boost Immunogens Increase Immunogenicity of a DNA/MVA HIV-1 Vaccine”, Journal of Virology., US, vol. 91, No. 24, doi: 10.1128/JVI.01077-17… [cited by applicant]
Ye, L. et al., “Ebola virus like particles produced in insect cells exhibit dendritic cell stimulating activity and induce neutralizing antibodies”, Virol., 351, 260-270, 2006. [cited by applicant]